<code id='94C492F039'></code><style id='94C492F039'></style>
    • <acronym id='94C492F039'></acronym>
      <center id='94C492F039'><center id='94C492F039'><tfoot id='94C492F039'></tfoot></center><abbr id='94C492F039'><dir id='94C492F039'><tfoot id='94C492F039'></tfoot><noframes id='94C492F039'>

    • <optgroup id='94C492F039'><strike id='94C492F039'><sup id='94C492F039'></sup></strike><code id='94C492F039'></code></optgroup>
        1. <b id='94C492F039'><label id='94C492F039'><select id='94C492F039'><dt id='94C492F039'><span id='94C492F039'></span></dt></select></label></b><u id='94C492F039'></u>
          <i id='94C492F039'><strike id='94C492F039'><tt id='94C492F039'><pre id='94C492F039'></pre></tt></strike></i>

          hotspot

          hotspot

          author:explore    Page View:6
          insulin biosimilar
          Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

          Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

          Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

          advertisement

          Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Adults seen as increasingly susceptible to measles
          Adults seen as increasingly susceptible to measles

          MikeReddyforSTATSimonMatthewsmadethreetripsthisspringtotheemergencyroomofhislocalhospitalinEastbourn

          read more
          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more

          Elevance, SCAN deals highlight health insurer acquisition scrutiny

          AdobeAdealisneverreallydoneuntilit’sdone.OnTuesday,twodifferentproposedinsuranceplanacquisitionsondi